NCT06540963 2026-03-02
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Milton S. Hershey Medical Center
Phase 2 Recruiting
Clinical Trials
8 trialsNCT03363373 2026-02-19
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Y-mAbs Therapeutics
Phase 2 Recruiting
NCT06528496 2026-02-10
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05489887 2026-02-03
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT02502786 2025-10-07
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03033303 2025-10-07
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT06013618 2025-06-17
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Sun Yat-sen University
Phase 2 Recruiting
NCT05968768 2025-04-10
To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)
Institute of Mother and Child, Warsaw, Poland
Phase 2 Recruiting